Aktis Oncology, Inc.
AKTS · United States
Share price · AKTS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AKTS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+6.6%
Nothing announced by AKTS that day or the session before.
- 2 Nov 2026-8.4%
Nothing announced by AKTS that day or the session before.
- 6 Jul 2026-16.4%
Nothing announced by AKTS that day or the session before.
- 16 Jun 2026+9.4%
Nothing announced by AKTS that day or the session before.
- 12 Jun 2026+12.7%
Nothing announced by AKTS that day or the session before.
- 12 May 2026+8.0%
- 9 Jan 2026+639900.0%
Nothing announced by AKTS that day or the session before.
Share of unusual movement by asset
For each asset, the share of AKTS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
AKY-1189events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 100% |
| Sessions with no dated event | — | 0% |
Assets
(2 total)
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $3.9M | $32M | $69M+ $425M short-term inv. | $30M-$26M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $3.4M | $25M | $84M+ $435M short-term inv. | $24M-$21M operating cash flow | report ↗ |
| 2026-Q1 | $3.2M | $20M | $373M+ $167M short-term inv. | $18M-$24M operating cash flow | report ↗ |
| 2025-Q3 | $1.6M | $16M | $181M | $16M-$15M operating cash flow | report ↗ |
| 2025-Q2 | $1.6M | $19M | $111M | $18M-$16M operating cash flow | report ↗ |
| 2025-Q1 | $1.4M | $16M | $59M | $15M-$17M operating cash flow | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $39M | — | report ↗ |
For the year ended December 31, 2025, Aktis Oncology reported collaboration revenue of $6.5M, up from $1.5M in 2024; R&D expenses of $67.5M, up from $41.0M; and a net loss of $63.7M, compared to $44.0M in 2024. Cash, cash equivalents and marketable securities totaled $226.8M at year-end, with a pro forma adjusted cash position of $562.1M after incorporating approximately $335.3M in net proceeds from the January 2026 IPO.
The FDA cleared IND applications for AKY-2519, a B7-H3-targeting miniprotein radioconjugate, allowing a Phase 1b trial expected to start in mid-2026, while the lead candidate AKY-1189 continues enrolling in a Phase 1b study and received Fast Track designation in February 2026, with preliminary Part 1 data expected in the first quarter of 2027. Management also guided that the pro forma adjusted cash position should fund operations into 2029, and it anticipates clinical imaging/dosimetry results for AKY-2519 in mid-2026, two early pipeline programs to reach development candidate nomination in Q1 2027, and an in-house GMP facility to be operational in the second half of 2026.
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $38M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 9 purchases ($114.3M), 11 sales ($3.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Feldman Paul L · Chief Scientific Officer | Option exercise | 55,035 | $1.90 | $105K | Form 4 |
| 2026-11-18 | Feldman Paul L · Chief Scientific Officer | Option exercise (derivative) | 55,035 | — | — | Form 4 |
| 2026-09-23 | Czibere Akos · Chief Medical Officer | Option exercise | 12,500 | $4.95 | $62K | Form 4 |
| 2026-09-23 | Czibere Akos · Chief Medical Officer | Open-market sale | 5,099 | $20.19 | $103K | Form 4 |
| 2026-09-23 | Czibere Akos · Chief Medical Officer | Open-market sale | 7,401 | $21.03 | $156K | Form 4 |
| 2026-09-23 | Czibere Akos · Chief Medical Officer | Option exercise (derivative) | 12,500 | — | — | Form 4 |
| 2026-07-20 | Herrmann Ken · director | Option exercise | 3,506 | $0.08 | $280 | Form 4 |
| 2026-07-20 | Herrmann Ken · director | Option exercise | 1,350 | $1.91 | $3K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 69 reporting institutions held 35.2M shares ($563.9M).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MPM BIOIMPACT LLC | 4,835,872 | $86.5M |
| 2 | EcoR1 Capital, LLC | 4,824,469 | $86.3M |
| 3 | Blue Owl Capital Holdings LP | 3,161,348 | $56.6M |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 2,317,044 | $41.5M |
| 5 | BlackRock, Inc. | 2,112,127 | $37.8M |
| 6 | RTW INVESTMENTS, LP | 1,592,043 | $28.5M |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 1,503,084 | $26.9M |
| 8 | JANUS HENDERSON GROUP PLC | 1,454,267 | $26.0M |
| 9 | BAKER BROS. ADVISORS LP | 996,351 | $17.8M |
| 10 | Octagon Capital Advisors LP | 960,847 | $17.2M |
| 11 | Avidity Partners Management LP | 937,132 | $17.2M |
| 12 | Merck & Co., Inc. | 952,844 | $17.0M |
| 13 | VANGUARD CAPITAL MANAGEMENT LLC | 833,913 | $14.9M |
| 14 | EVENTIDE ASSET MANAGEMENT, LLC | 507,000 | $9.1M |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 491,936 | $8.8M |